Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jan-Feb;87(1):42-48.
doi: 10.25259/IJDVL_787_19.

A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata

Sonali Bhat  1 , Sanjeev Handa  1 , Dipankar De  1
Affiliations
Free article
Randomized Controlled Trial

A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata

Sonali Bhat et al. Indian J Dermatol Venereol Leprol. 2021 Jan-Feb.
Free article

Abstract

Background: Topical corticosteroids are the standard therapy for the treatment of alopecia areata. Recently, topical latanoprost has been found effective in the treatment of eyelash alopecia areata.

Objectives: The objective of this study was to compare the efficacy of topical latanoprost ophthalmic solution (group 1) with that of topical betamethasone diproprionate lotion (group 2) in the treatment of localized alopecia areata.

Methods: This was a single-centre, randomized, two-armed, parallel-group efficacy trial. Fifty consecutive patients with localized alopecia areata were randomized in a 1:1 ratio to receive either topical latanoprost 0.005% ophthalmic solution or topical betamethasone diproprionate 0.05% lotion. Of these 50 patients, 44 patients (21 in group 1 and 23 in group 2) completed the treatment protocol.

Results: The percentage reduction in area involved with alopecia areata at 16 weeks (primary outcome) was lower in latanoprost vs. betamethasone group (median [interquartile range], 11.1 [0-99.1] vs. 100% [13.6-100], P = 0.02). Significantly lesser patients in the latanoprost group had a complete response to treatment as compared to the betamethasone group (6 [24%] vs. 14 [56%], P = 0.02). The median (interquartile range) hair regrowth score was significantly lower in the latanoprost vs. the betamethasone group (1 [0-4.5] vs. 5 [1-5], P = 0.02). Subjects in the betamethasone group showed a more rapid reduction in the involved area.

Limitations: Short duration of treatment and follow-up were limitations of this study.

Conclusion: Our results suggest that topical latanoprost 0.005% ophthalmic solution is less effective but safer than topical betamethasone dipropionate 0.05% lotion in the treatment of localized alopecia areata (clinicaltrials.gov: NCT02350023).

Keywords: Betamethasone; a prostaglandin analogue; corticosteroid; latanoprost; localized alopecia areata.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000; 42:549-66 - DOI - PubMed
    1. Hordinsky M, Donati A. Alopecia areata: An evidence-based treatment update. Am J Clin Dermatol. 2014; 15:231-46 - DOI - PubMed
    1. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008; 16:CD004413 - DOI - PubMed
    1. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997; 124:544-7 - DOI
    1. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997; 115:1206-8 - DOI - PubMed

Publication types

Associated data

LinkOut - more resources